With the in‐depth exploration of the biology of Mfsd2a and its mechanism of action in stroke, as well as the continuous emergence of innovative treatment technologies and translational research methods, targeting Mfsd2a is expected to provide a novel, safe, and effective BBB‐centric neuroprotective therapy for patients with ischemic stroke in the near future, ultimately improving patients' quality of life and long‐term prognosis. This evidence concerns the gene MFSD2A and stroke disorder.